Instytut Hematologii i Transfuzjologii – instytut badawczy w Warszawie podległy Ministerstwu Zdrowia specjalizujący się w hematologii i transfuzjologii. Jednostka istnieje od 1951. Do 1992 nosiła nazwę Instytut Hematologii. Obecnie Instytut posiada dwie siedziby: główną na Ursynowie przy ul.

During the past decade, Instytut Hematologii i Transfuzjologii conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 22 clinical trials were completed, i.e. on average, 52.4% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 14 clinical trials were completed. i.e. 93.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instytut Hematologii i Transfuzjologii" #1 sponsor was "Janssen Research & Development, LLC" with 7 trials, followed by "Takeda" with 5 trials sponsored, "Celgene" with 4 trials sponsored, "Amgen" with 3 trials sponsored and "Astex Pharmaceuticals, Inc." with 3 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instytut Hematologii i Transfuzjologii" #1 collaborator was "Takeda Development Center Americas, Inc." with 3 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator, "Andalusian Network for Design and Translation of Advanced Therapies" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Atlantic Research Group" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Instytut Hematologii i Transfuzjologii" are "Multiple Myeloma" (6 trials), "Acute Myeloid Leukemia" (5 trials), "Leukemia, Myeloid, Acute" (4 trials), "Lymphoma, Non-Hodgkin" (3 trials) and "Acute Myeloid Leukemia (AML)" (2 trials). Many other conditions were trialed in "Instytut Hematologii i Transfuzjologii" in a lesser frequency.

Most popular intervention types in "Instytut Hematologii i Transfuzjologii" are "Drug" (46 trials), "Biological" (6 trials), "Device" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Dexamethasone" (6 trials), "Azacitidine" (5 trials), "Bortezomib" (5 trials) and "Daratumumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Instytut Hematologii i Transfuzjologii" are 56 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Instytut Hematologii i Transfuzjologii". undefined are not yet recruiting, 11 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Instytut Hematologii i Transfuzjologii, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Instytut Hematologii i Transfuzjologii, 4 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".

Instytut Hematologii i Transfuzjologii has several departments that took part in Clinical trials: "Institute of Hematology and Transfusion Medicine" - 24 trials, "Instytut Hematologii i Transfuzjologii; Klinika Hematologii" - 10 trials, "Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych" - 9 trials